ABSTRACT
Chronic lymphocytic leukaemia (CLL), the most frequent type of adult leukaemia in Western countries, is a clonal haematopoietic disorder with proliferation and accumulation of small lymphocytes usually of B-cell lineage [1-3]. Use of innovative dose-intensive therapies requires justification, and careful evaluation of patients should be made if these treatment approaches are being considered.
